Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 168

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19

Open access
Keith, Philip, Day, Matthew, Perkins, Linda, Moyer, Lou, Hewitt, Kristi, Wells, Adam · 2020 · Critical Care

Abstract

The novel coronavirus (“SARS-CoV-2”) outbreak has created a sense of panic globally and has the medical community rapidly searching for answers. An estimated 100,000 individuals have already been infected with nearly 3300 deaths attributed to the disease (termed COVID-19) [1]. The search for effective treatment is underway with multiple investigations ongoing across the world. Chinese authorities have reported success treating infected patients with donated plasma from survivors of the illness, the proposed benefit being protective antibodies formed by the survivors [2]. Plasma transfusion and blood purification are not novel therapies, and we propose therapeutic plasma exchange as a possible treatment for fulminant COVID-19. With COVID-19, the degree of illness varies, ranging from asymptomatic to fulminant and fatal. The World Health Organization estimates that serious illness may occur in as many as 13.8% of cases and 6.1% are critical [3]. When fulminant, patients may develop sepsis, acute respiratory distress syndrome (ARDS), and/or multiple organ failure which are not unique to coronavirus. While treatment of the virus itself is certainly desired, treatment of the systemic response is likely to be the more important aspect of care and should be aggressively sought. This host response to infection has been well described and involves a complex interaction of cytokine storm, inflammation, endothelial dysfunction, and pathologic coagulation [4–8]. The pathway is common to multiple inciting events and has been the target of treatment for years, with therapeutic plasma exchange uniquely offering benefit on multiple levels by removing inflammatory cytokines, stabilizing endothelial membranes, and resetting the hypercoagulable state [4, 8, 9]. An in-depth review is beyond the scope of this editorial, but the reader is encouraged to review the referenced articles. Figure 1 briefly illustrates the pathway. Busund and colleagues showed a tendency toward improved mortality with adjunct TPE in adult patients with sepsis and multiple organ failure in the sole, adult-only randomized controlled trial on this subject [10] while a meta-analysis by Rimmer showed mortality benefit in adult patients as well [11]. Drawing from this data, Patel and colleagues utilized TPE during the 2009 H1N1 influenza A outbreak in three pediatric patients presenting in a similar fashion to those seen with fulminant COVID-19 today [12]. All three patients developed ARDS with hemodynamic compromise that continued to deteriorate despite standard care and rescue therapy for ARDS including inhaled nitric oxide (3/3) and veno-venous ECMO (1/3). Predicted mortality was high, but all three had full recovery from their illness after receiving rescue TPE. Others have reported successful outcomes, feasibility, and safety of TPE for sepsis, but none have investigated specifically in pneumonia/ARDS. Our group has recently submitted the results of our single-center experience with TPE in sepsis with multiple organ failure with the manuscript currently under consideration for publication with preprint available online (DOI: https://doi.org/ 10.21203/rs.3.rs-16022/v1) [13]. In our trial, charts were retrospectively reviewed and patients receiving adjunct TPE were propensity matched to patients with similar illness who received standard of care alone. Full details are available online, but it should be noted that all

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13054-020-2836-4

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 168

Metadata

Authors
Keith, P., Day, M., Perkins, L., Moyer, L., Hewitt, K., & Wells, A.
Venue
Critical Care
Published
2020-04-02
Volume
24
Issue
1
Pages
128-128
ISSN
1364-8535 (ISSN-L)
OpenAlex
W3013601745
Cited by
168
References
1
FWCI
4.80
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19. https://app.cochat.ai/papers/10.1186/s13054-020-2836-4
The paper
Keith, P., Day, M., Perkins, L., Moyer, L., Hewitt, K., & Wells, A. (2020). A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19. Critical Care. https://doi.org/10.1186/s13054-020-2836-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.